INCYIncyte CorporationFinished
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 453 (final count)
- Started
- Nov 28, 2016
- Main results expected
- Jun 21, 2024
- Fully finished
- Jun 21, 2024
- Results posted
- Jul 17, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall Population
Measured over: up to 41.4 months
Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Natural Killer Cell Count-Low Subgroup
Measured over: up to 46.5 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02763319 · record last updated 2025-07-17 · checked 2026-11-09 15:47 UTC